Streetbeat News

Products Services

MSFT

OpenAI and Microsoft Corporation (NASDAQ:MSFT) are being sued by author Julian Sancton for copyright infringement, alleging they used non-fiction authors' works to train their AI systems without permission. Sancton seeks damages and a court order to stop the infringement. This lawsuit is the first to involve Microsoft, a major investor in OpenAI, which has integrated OpenAI's technology into its products. OpenAI and Microsoft have faced similar allegations before but have denied them.

Portfolio Pulse from Ananya Gairola

November 22, 2023 | 2:49 am

TSLA

Tesla Inc (NASDAQ:TSLA) is offering up to $3,000 discounts on Model Y inventory vehicles in the US. This comes alongside a $7,500 tax credit available for these vehicles. The discounts are likely in response to concerns about falling demand due to rising interest rates, as mentioned by CEO Elon Musk during the Q3 earnings call. Despite price cuts, monthly payments remain similar due to the higher interest rates. Tesla's stock closed 2.38% higher at $241.20 on Tuesday.

Portfolio Pulse from Anan Ashraf

November 22, 2023 | 2:44 am

TSLA

Dogecoin (DOGE) recently surpassed 8 cents, reaching highs not seen since April. Tesla Inc (TSLA) and Dogecoin are linked due to Elon Musk's support. Although DOGE can't currently be used to buy Tesla vehicles, it can be used for merchandise purchases. An investment in DOGE today could potentially allow an investor to afford a Tesla Model Y if DOGE reaches $0.25. To buy a Model Y priced at $43,990, an investor would need 175,960 DOGE, which would require an investment of $13,114.77 at the current DOGE price of $0.07452.

Portfolio Pulse from Chris Katje

November 22, 2023 | 12:40 am

SENEA

SENEB

Seneca Foods Corporation has initiated a voluntary recall of mislabeled Hy-Vee Turkey Gravy, which actually contains beef gravy and an undeclared soy allergen. The recall is limited to 12 oz glass jars with specific lot codes and affects only Hy-Vee sold products. No consumer illnesses have been reported.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 11:13 pm

NVDA

During Nvidia's conference call, the CFO announced that their networking segment has surpassed a $10 billion annualized revenue run rate. Additionally, the company's software support and services are projected to reach a $1 billion annual run rate.

Portfolio Pulse from Charles Gross

November 21, 2023 | 10:21 pm

DIS

Disney expects to spend approximately $25 billion on produced and licensed content in fiscal 2024, with capital expenditures projected to be around $6 billion, as reported in its 10-K filing.

Portfolio Pulse from Charles Gross

November 21, 2023 | 10:17 pm

DIS

Disney is planning to expand its ad-supported Disney+ service to more international markets in 2024. This move is expected to increase the platform's user base and revenue by offering a more affordable subscription option.

Portfolio Pulse from Charles Gross

November 21, 2023 | 10:15 pm

CERT

Certara, Inc. (NASDAQ:CERT) has launched Simcyp Biopharmaceutics software, a new addition to its Simcyp Simulator biosimulation platform. This software aids biopharmaceutic, formulation, and CMC scientists in efficiently formulating both novel and generic small molecule medicines. It offers capabilities such as virtual bioequivalence studies to replace costly clinical trials, optimization of formulations for complex drugs, and informing drug labels with PBPK models. The software is recognized for supporting label claims for over 100 approved therapies and is available as a standalone product.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 9:33 pm

AL

BA

Air Lease Corporation (ALC) has delivered the first of 25 new Boeing 737-8 aircraft to Malaysia Airlines Berhad. This aircraft is in addition to the six Airbus A350-900 aircraft that are already on long-term lease from ALC to the airline.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 9:32 pm

LUMO

Lumos Pharma, Inc. (NASDAQ:LUMO) is set to host a virtual KOL webinar to discuss the Phase 2 OraGrowtH trial data for its oral therapeutic candidate LUM-201, aimed at treating moderate Pediatric Growth Hormone Deficiency (PGHD). The event will feature three endocrinology experts and will take place on December 6, 2023, at 1:30 PM EST.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 9:29 pm